Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIGIN: Lenalidomide vs Chlorambucil as First-Line Therapy in Elderly B-cell CLL
2008-003079-32Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenalidomide in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Started May 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2008-003079-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003079-32.